JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

IRBESARTAN; HYDROCHLOROTHIAZIDE

Доступна з:

JAMP PHARMA CORPORATION

Код атс:

C09DA04

ІПН (Міжнародна Ім'я):

IRBESARTAN AND DIURETICS

Дозування:

300MG; 25MG

Фармацевтична форма:

TABLET

Склад:

IRBESARTAN 300MG; HYDROCHLOROTHIAZIDE 25MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

28/100

Тип рецепту:

Prescription

Терапевтична области:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Огляд продуктів:

Active ingredient group (AIG) number: 0240086003; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2022-09-06

Характеристики продукта

_Jamp-Irbesartan and Hydrochlorothiazide _
_Page 1 of 40_
PRODUCT MONOGRAPH
PR
JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLETS
(House Standard)
150/12.5 mg, 300/12.5 mg and 300/25 mg
Angiotensin II AT
1
Receptor Blocker / Diuretic
JAMP PHARMA CORPORATION
DATE OF PREPARATION:
1380-203 NEWTON,
BOUCHERVILLE, QUÉBEC, J4B 5H2
December 11, 2013
SUBMISSION CONTROL NO.: 170093
_Jamp-Irbesartan and Hydrochlorothiazide _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
9
DRUG INTERACTIONS
............................................................................................................
13
DOSAGE AND ADMINISTRATION
........................................................................................
16
OVERDOSAGE
...........................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
19
STORAGE AND STABILITY
....................................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 22
PART II: SCIENTIFIC INFORMATION
.......................................................................................